Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;54(Suppl 2):759-764.
doi: 10.1038/s41409-019-0614-1.

Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction

Richard J O'Reilly  1 , Susan Prockop  2 , Aisha Hasan  2 , Ekaterina Doubrovina  2
Affiliations
Review

Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction

Richard J O'Reilly et al. Bone Marrow Transplant. 2019 Aug.

Abstract

We have developed banks of EBV and CMV-specific T-cell lines generated from healthy seropositive third party donors and characterized them as to their HLA type, virus specificity, lack of alloreactivity, and HLA restriction. We here summarize results of studies employing these immediately accessible, broadly-applicable third party virus-specific T-cells for adoptive therapy of EBV lymphomas and CMV infections in allo-HCT recipients. We describe the characteristics contributing to their safety. We also discuss several distinctive advantages of banked third party virus-specific T-cells selected on the basis of their HLA restriction, particularly in the treatment of Rituximab-non-responsive EBV+ lymphomas and drug refractory CMV infections complicating HLA non-identical transplants.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE

Conflicts of Interest: RJO’R received consulting fees and grant support from Atara Biotherapeutics, Starr Cancer Consortium, and POl CA23766. When Atara Biotherapeutics licensed banks of EBV and CMV T-cells, RJO’R received a part of the royalties paid to Memorial Sloan Kettering Cancer Center. MSKCC also has several patents of which RJO’R is an inventor bearing on the T-cells. SP received grant support from Atara Biotherapeutics, Mesoblast, and Janssen Pharmaceuticals. SP was an inventor for patents held by MSK but does not receive royalties or income for the inventions. ANH received grant support from Atara Biotherapeutics, holds patents and received royalties for Virus Specific T cell work with Atara Biotherapeutics. ED received grant support and consulting fees from Atara Biotherapeutics. ED also has patents, of which, the author is a co-inventor bearing on the T-cells and received a part of payments to Memorial Sloan Kettering Cancer Center from Atara Biotherapeutics.

References

    1. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–41. - PubMed
    1. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. The New England journal of medicine. 1994;330(17):1185–91. - PubMed
    1. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (London, England). 1995;345(8941):9–13. - PubMed
    1. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet (London, England). 2003;362(9393):1375–7. - PubMed
    1. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360–7. - PubMed

MeSH terms

Substances